TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Provider review

MEDVi tirzepatide review

What MEDVi charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

We re-read MEDVi’s own pages on November 20, 2026. MEDVi’s price page could not be read on November 20, 2026 (it renders prices only in a browser session). MEDVi is not scored in our November 20, 2026 computed ranking because it has no compounded tirzepatide price we could read on its own pages that day. Sections below that show July 2026 records are kept as dated history.

Answer last reviewed:
Methodology scorev4.1 · read the methodology
v4.1 re-score pending
Pricing transparency—/20
Total annual cost—/20
Clinical oversight—/15
Pharmacy transparency—/15
Support—/10
Regulatory disclosure—/10
Accessibility—/10
Not yet re-scored on methodology v4.1. Programs other than NexLife are listed alphabetically until they are.

What is distinctive about this programme

Two figures we will not assert

Our source dataset flags MEDVi's $399 tirzepatide rate as not appearing on the current GLP-1 landing page, and its $369 oral semaglutide rate as third-party reporting rather than a direct capture. We have imported both as pending rather than reported, which means they do not appear in any ranking or comparison on this site.

That is the correct handling and it is also the useful information: a price that cannot be found on the provider's own page is not a price a patient can rely on. Verify at intake.

Escalating pricing at higher doses

The tirzepatide programme is reported as a refill rate at lower doses reaching $499 at 10, 12.5 and 15 mg. If accurate, that places it among the most expensive compounded programmes in the market at exactly the doses most patients reach — well above brand Zepbound at $449 direct from LillyDirect.

Introductory rates

The $179 first-month semaglutide rate rises to $299 ongoing, and the $249 first-month oral rate to $369. Both are excluded from our rankings, as all introductory rates are.

MEDVi — every captured offering, monthlyCaptured 2026-07-06
Semaglutide injectable$299Semaglutide oral / ODT$369Tirzepatide injectable$399
Show this figure as a table
Data table
ItemValueEvidence
Semaglutide injectable$299Reported
Semaglutide oral / ODT$369Pending
Tirzepatide injectable$399Pending
Formulations are not interchangeable. A microdose price is never compared against a standard injectable price, here or anywhere on this site.

Where it holds up

  • Publishes a refill rate structure rather than a single ambiguous figure
  • Semaglutide ongoing pricing is clearly stated

Where it does not

  • Tirzepatide pricing could not be found on the current landing page and is marked pending
  • Reported escalation to $499 at maintenance doses exceeds brand Zepbound direct
  • Introductory first-month rates are substantially below ongoing rates
  • Oral semaglutide figure is third-party reported rather than captured
  • Figures are third-party reported and not yet captured by us
How this provider prices, in one table
How this provider prices, in one table
FieldPosition
MembershipSeparate and required
Dose structureEscalates with dose or not established
Lowest captured figure$299/mo, month-to-month
Evidence statusThird-party reported, pending our own capture
Pharmacy named to usNo — provider-reported only
Every field moves to verified only when a named researcher captures it and archives the source.
How the 100 points are allocatedMethodology v4.1
Pricing transparency20 ptsTotal annual cost20 ptsClinical oversight15 ptsPharmacy transparency15 ptsSupport10 ptsRegulatory disclosure10 ptsAccessibility10 pts
Show this figure as a table
Methodology v4.1 weights
CategoryPoints
Pricing transparency20 pts
Total annual cost20 pts
Clinical oversight15 pts
Pharmacy transparency15 pts
Support10 pts
Regulatory disclosure10 pts
Accessibility10 pts
Seven weighted categories, 100 points. NexLife scores 94; other programs are listed alphabetically while their v4.1 re-scores are pending. Read the methodology

Pricing, all-in

Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.

MEDVi — every captured pricing record
ProviderProgramFormulationDose coverageMedicationRequired feesAll-in monthlyPrice typeEvidenceCaptured
MEDVimonth_to_monthcompounded injectable—$399—$399RecurringPending—
MEDVimonth_to_monthcompounded injectable—$299—$299RecurringReported2026-07-06
MEDVimonth_to_monthcompounded oral / ODT—$369—$369RecurringPending—

How this sits against the market

Lowest all-in monthly price, compounded tirzepatide, 33 programsPrice index, October 15, 2026; NexLife November 6, 2026
Collective$85.58WellMedr$89Mondae$114NexLife$115Embody$119NextMeds$119SnagRx$119yourEra$123NewMeMeds$125CoreAge Rx$129Eden Health$129SkinnyRx$129GobyMeds$133Telos RX$139Sprout Health$149Strut Health$149He & She MD$159Bodybuilding Health+$174.67bmiMD$179IVIM Health$192Alloy$199TelePep$214Yucca Health$225Found$239Pallas Health$239ShedRx$239MyDrHank$240Enhance.MD$280
Show this figure as a table
Lowest all-in monthly price by program, sorted low to high
ProgramAll-in monthlyRead
Collective$85.58Read 2026-10-15
WellMedr$89Read 2026-10-15
Mondae$114Read 2026-10-15
NexLife$115Read 2026-11-06
Embody$119Read 2026-10-15
NextMeds$119Read 2026-10-15
SnagRx$119Read 2026-10-15
yourEra$123Read 2026-10-15
NewMeMeds$125Older record, 2026-09-20
CoreAge Rx$129Read 2026-10-15
Eden Health$129Read 2026-10-15
SkinnyRx$129Older record, 2026-08-27
GobyMeds$133Read 2026-10-15
Telos RX$139Read 2026-10-15
Sprout Health$149Read 2026-10-15
Strut Health$149Read 2026-10-15
He & She MD$159Read 2026-10-15
Bodybuilding Health+$174.67Read 2026-10-15
bmiMD$179Older record, 2026-09-17
IVIM Health$192Read 2026-10-15
Alloy$199Read 2026-10-15
TelePep$214Read 2026-10-15
Yucca Health$225Older record, 2026-09-12
Found$239Read 2026-10-15
Pallas Health$239Read 2026-10-15
ShedRx$239Read 2026-10-15
MyDrHank$240Older record, 2026-09-17
Enhance.MD$280Read 2026-10-15
Lowest figure each program prints for standard compounded tirzepatide, with annual memberships spread over 12 months. Sorted by price, not by our ranking. Some figures are sale prices or need prepayment; see the price index.
What MEDVi charges, component by component
Medication—Membership—Shipping—Dose surcharge—Consultation—Labs—Structure only. No widths are proportional to anything, because nothing is captured.
Show this figure as a table
Data table
ComponentAmount
Medicationnot captured
Membershipnot captured
Shippingnot captured
Dose surchargenot captured
Consultationnot captured
Labsnot captured
All-in totalnot captured
A provider that advertises only the first segment is quoting a price you cannot actually pay.
Where a headline price usually stops short
Where a headline price usually stops short
Cost componentInside the advertised figure?Charged anyway?
Medicationyesyes
Membership or program feeno—
Shippingno—
Higher-dose surchargeno—
Initial consultationno—
Required laboratory workno—
Cancellation or restocking termsno—

A dash means no figure held. How we grade evidence.

The right-hand column fills in per provider as capture proceeds. Until then it reads unverified, which is the honest state.
Verified price historyPending
no verified captures yet

This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.

Against the category median
All-in monthlyThis provider — not capturedCategory median — not capturedMembership feeThis provider — not capturedCategory median — not capturedRubric scoreThis provider — not capturedCategory median — not capturedThis providerCategory median
Show this figure as a table
Data table
ItemThis providerCategory median
All-in monthlynot capturednot captured
Membership feenot capturednot captured
Rubric scorenot capturednot captured
Medians publish once enough of the comparison set is captured to make a median mean something.

What is included, and what is not

Where it holds up

  • nothing verified yet

Where it does not

  • nothing verified yet

Where it operates

State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.

State research coverage
Researched and verified — 0 (0%)Not yet researched — 51 (100%)51records
Show this figure as a table
Where it operates
StatusRecordsShare
Researched and verified00%
Not yet researched51100%
51 jurisdictions, each researched separately. A shared rule still needs its own source.

Clinical model

Pharmacy and fulfilment

Billing, cancellation and support

What changed

Verified changes to this provider's terms
no dated events recorded yet
Show this figure as a table
What changed
No events recorded.
Events appear here when something dated actually happens, not to refresh a timestamp.
  • no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.

How this compares to the category

Once enough providers are scored, this section reports where MEDVi sits against the median for each rubric category, not against a hand-picked competitor.

What we have asked MEDVi, and what they have answered0 of 55 available points unlocked
What we have asked MEDVi, and what they have answered
QuestionWorthTheir answerStatus
Pharmacy traceability and quality disclosures15 pts—Not answered Pending
Clinical oversight and care continuity20 pts—Not answered Pending
State access and operational reliability10 pts—Not answered Pending
Cancellation, billing and support transparency10 pts—Not answered Pending

A dash means no figure held. How we grade evidence.

Blank cells are the answer we have, which is none. This provider can change any row by replying — see the disclosure register for the exact questions and what an answer changes.

Questions readers actually ask

Is MEDVi the cheapest option?

We will not answer that until the all-in figures are captured for the whole comparison set. A cheapest claim needs a defined comparison group, a stated program type and a capture date, or it is just an adjective.

Is this review sponsored?

No. Reviews here are not sponsored, and no provider can buy a score, a placement or a review. Tirzepatide Ranked is affiliate-supported; the disclosure page explains how.

Is compounded tirzepatide the same as Zepbound?

No. Compounded preparations are not FDA-approved products and there is no generic tirzepatide. Approval of the brand product does not extend to a compounded preparation.

Cite this pageCC BY 4.0

Tirzepatide Ranked. “MEDVi Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/providers/medvi/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.

Comparing 0 of 4